Nephrogenic Systemic Fibrosis

Representing the Injured in Nevada

A dye used in MRI (magnetic resonance imaging) and MRA (magnetic resonance angiography) scans has been linked to a rare and potentially fatal skin disease in some users (1).

The problem stems from the metal gadolinium found in the dyes injected into some patients before MRI scans and all patients before MRA scans.

The disease is known as nephrogenic systemic fibrosis or nephrogenic fibrosing dermopathy (NSF/NFD), and appears to only occur in patients with kidney disease who undergo an MRI or MRA where a gadolinium-based dye is used (1). Most recently, the medical community, in recognizing the established link between NSF and gadolinium dyes, has started referring to the condition as “gadolinium-associated systemic fibrosis,” or GASF.

These dyes, known as “contrast agents,” are commonly injected into patients shortly before they undergo MRI or MRA scans, which are frequently used as a noninvasive procedure for doctors to see inside the body to look for many problems, such as tumors, internal organ complications, clogged arteries, brain irregularities, and more.

The Food and Drug Administration (FDA) states in a public health advisory: “Patients with moderate to end-stage kidney disease who receive an MRI or MRA with a gadolinium-based contrast agent may get NSF/NFD, which is debilitating and may cause death (1).”

Update 11/23/09:

A study published in the Archives of Dermatology demonstrated a 77-fold higher risk of NSF/NFD among patients who undergo hemodialysis and a 69-fold higher risk in patients with renal transplantation.

The FDA later asked for a boxed warning to be included in all gadolinium-based contrast agents to warn of the potential of NSF in some patients. The FDA then asked the manufacturers to include a black box warning (the strongest warning possible) on all gadolinium-based products. The warning notes that these dyes may increase the risk of potentially fatal side effects in patients with certain kidney and liver conditions.

NSF/NFD Symptoms

The International Center for Nephrogenic Fibrosing Dermopathy Research describes the symptoms of NSF/NFD as, “Swelling and tightening of the skin, usually limited to the extremities, but sometimes involving the trunk. Severely affected patients may be unable to walk, or fully extend the joints of their arms, hands, legs, and feet (2).” NSF/NFD may develop over the course of several weeks.

The skin's texture may also change to a wood-like consistency or feel like an orange peel. Accompanying these symptoms are sensations of burning, itching, and severe sharp pains in specific areas. Deep “bone pain” of the hips and ribs has also been reported (2). Severe cases can be fatal.

Talk to a Lawyer

Our law firm is actively investigating cases of patients administered a gadolinium-based contrast dye who later suffered from nephrogenic systemic fibrosis or nephrogenic fibrosing dermopathy (NSF/NFD). We want to help. Call us today.

Sources:

1) Public health advisory, update on magnetic resonance imaging (MRI) contrast agents containing gadolinium and nephrogenic fibrosing dermopathy, from the FDA Web site (www.FDA.gov). Accessed 4/17/07.

2) The International Center for Nephrogenic Fibrosing Dermopathy Research Web site, by Shawn E. Cowper, MD, Assistant Professor of Dermatology and Pathology at Yale University. Accessed 4/17/07 via the Official site of the Nephrogenic Fibrosing Dermopathy (NFD/NSF) Registry.

This law firm is not affiliated with, sponsored by, or associated with the Food and Drug Administration or the International Center for Nephrogenic Fibrosing Dermopathy Research.

Free Consultation

When you hire Richard Harris Law Firm, you get more than a Las Vegas injury lawyer—you get a partner who will work with you throughout your entire case. We have helped injured victims get the compensation they need for more than 30 years, and our Nevada injury lawyers are here for you, too. Don’t hesitate. Fill out an online consultation form or call (702) 444-4444 for a free and confidential case evaluation today.